StockData

Can-Fite BioPharma vs CytoMed Therapeutics

CANF and GDTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CANF and GDTC compare

CytoMed Therapeutics grew revenue faster over the last twelve months (367% versus −39.9% for Can-Fite BioPharma).

CytoMed Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1227% compared with −2427% at Can-Fite BioPharma.

CytoMed Therapeutics scores higher on the StockData Score (4 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCANFGDTC
Size and price
Share price$1.53$0.783
Change, 1 year−79.3%−60.1%
Change, 5 years−99.4%–
Beta (5Y)1.47−0.42
Employees55
StockData Score
Total score14 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score12 (better)
Dividend score00
Growth
Revenue growth (TTM)−39.9%367% (better)
Revenue growth, 5Y average−11.9%–
Profitability
Operating margin−2457%–
Net margin−2427%−1227% (better)
FCF margin−2210%−1336% (better)
Return on equity−217%−51.3% (better)
Financial health
Debt / equity–0.06
Interest coverage−35.0×–
Current ratio3.605.17 (better)
Piotroski F-score2 (better)1
Ownership
Held by institutions1.9%0.10%
Held by insiders0.00%25.9%
Insider net buying, 12 months–$729K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.